Literature DB >> 8850381

Iloprost antagonizes the increase in internal calcium concentration induced by alpha-thrombin in human platelets: a study of desensitization.

E Cecchi1, L Capone, C Ruocco, A Fazzini, A Mugelli, A Giotti, P Failli.   

Abstract

We studied the interaction between the synthetic prostacyclin analog iloprost and the aggregating agent alpha-thrombin by measuring the internal calcium ion concentration ([Ca(2+)]i) of human fura-2-loaded platelets. Iloprost (0.003-100 micrograms/l) did not modify the resting calcium level; when added 2 minutes before exposure of the platelets to a submaximally active concentration of alpha-thrombin (10 U/l), iloprost dose-dependently antagonized the increase in [Ca(2+)]i. To evaluate if iloprost retained this antagonistic effect even after a prolonged contact, which is well known to cause a "desensitization" phenomenon, platelets were preincubated with iloprost (35 micrograms/l) for 3 hours. After washout, the effect of newly added iloprost (0.01-100 micrograms/l) on the alpha-thrombin-induced increase in [Ca(2+)]i was tested. Iloprost was still able to antagonize the increase in [Ca(2+)]i induced by alpha-thrombin in "desensitized" platelets; however, the dose-inhibitory response curve was significantly shifted to the right when compared with that obtained in control platelets (i.e., platelets preincubated for 3 hours with iloprost's solvent), and the resulting IC50 was significantly higher: 1.78 versus 0.2 micrograms/l (p < 0.001). Since the maximal inhibitory effect of iloprost could also be reached under these experimental conditions, we conclude that iloprost retains its ability to antagonize the increase in [Ca(2+)]i induced by alpha-thrombin in desensitized platelets.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8850381     DOI: 10.1007/bf00879870

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  16 in total

Review 1.  Second European Consensus Document on chronic critical leg ischemia.

Authors: 
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

2.  Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost in vitro.

Authors:  U Alt; P J Leigh; A J Wilkins; P K Morris; J MacDermot
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

3.  Desensitization of prostacyclin responsiveness in platelets. Apparent differences in the mechanism in vitro or in vivo.

Authors:  J MacDermot
Journal:  Biochem Pharmacol       Date:  1986-08-15       Impact factor: 5.858

Review 4.  Molecular mechanisms of platelet activation.

Authors:  W Siess
Journal:  Physiol Rev       Date:  1989-01       Impact factor: 37.312

5.  Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase.

Authors:  K Jaschonek; C Faul; H Schmidt; W Renn
Journal:  Eur J Pharmacol       Date:  1988-03-01       Impact factor: 4.432

6.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

Review 7.  Calcium signaling in human platelets.

Authors:  T J Rink; S O Sage
Journal:  Annu Rev Physiol       Date:  1990       Impact factor: 19.318

8.  Effects of L- and D-arginine and some related esters on the cytosolic mechanisms of alpha-thrombin-induced human platelet activation.

Authors:  P Failli; E Cecchi; C Ruocco; A Fazzini; A Giotti
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

9.  The relaxing activity of iloprost and prostaglandin E2 in the isolated various smooth muscle strips of the rabbit.

Authors:  Z S Ercan; R K Türker
Journal:  Pharmacology       Date:  1985       Impact factor: 2.547

10.  cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla.

Authors:  T Namba; H Oida; Y Sugimoto; A Kakizuka; M Negishi; A Ichikawa; S Narumiya
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.